Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma

Jayadev M. Umakanthan, Javeed Iqbal, Connie L. Batlevi, Alyssa Bouska, Lynette M Smith, Valerie Shostrom, Heather Nutsch, Basem M. William, Robert G Bociek, Matthew A Lunning, Philip Jay Bierman, Anas Younes, James Olen Armitage, Julie Marie Vose

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. The most common sub-types were diffuse large B-cell lymphoma (24%), follicular lymphoma, grade 1/2 (21%) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; 21%). Most patients were heavily pre-treated, including 42% with more than four prior therapies, 67% with rituximab exposure and 24% with prior autologous transplant. In this cohort, dasatinib showed modest activity in evaluable patients with an objective response rate of 29% (7/24) and clinical benefit rate of 71% (17/24). In 32 patients with outcome data, median progression-free survival was 3 months and median overall survival was 22·4 months. There were two patients with sustained complete responses, both with PTCL-NOS histology. The side effect profile was consistent with prior studies, with pleural effusion being the most common non-haematological toxicity. Exploratory genomic analysis showed two cases of PTCL-NOS with sustained response had a common mutation in LRRK2 and high prevalence of FOXO1 mutation in relapsed/refractory follicular lymphoma.

Original languageEnglish (US)
Pages (from-to)744-752
Number of pages9
JournalBritish Journal of Haematology
Volume184
Issue number5
DOIs
StatePublished - Mar 2019

Fingerprint

Non-Hodgkin's Lymphoma
Follicular Lymphoma
Peripheral T-Cell Lymphoma
Mutation
Lymphoma, Large B-Cell, Diffuse
Autografts
Pleural Effusion
Disease-Free Survival
Histology
Phosphotransferases
Dasatinib
Safety
Survival
Therapeutics

Keywords

  • NHL
  • dasatinib
  • mutation analysis
  • phase 2 study
  • relapsed/refractory lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. / Umakanthan, Jayadev M.; Iqbal, Javeed; Batlevi, Connie L.; Bouska, Alyssa; Smith, Lynette M; Shostrom, Valerie; Nutsch, Heather; William, Basem M.; Bociek, Robert G; Lunning, Matthew A; Bierman, Philip Jay; Younes, Anas; Armitage, James Olen; Vose, Julie Marie.

In: British Journal of Haematology, Vol. 184, No. 5, 03.2019, p. 744-752.

Research output: Contribution to journalArticle

@article{bb79ceae63144edc9f07497a222f74e4,
title = "Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma",
abstract = "Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. The most common sub-types were diffuse large B-cell lymphoma (24{\%}), follicular lymphoma, grade 1/2 (21{\%}) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; 21{\%}). Most patients were heavily pre-treated, including 42{\%} with more than four prior therapies, 67{\%} with rituximab exposure and 24{\%} with prior autologous transplant. In this cohort, dasatinib showed modest activity in evaluable patients with an objective response rate of 29{\%} (7/24) and clinical benefit rate of 71{\%} (17/24). In 32 patients with outcome data, median progression-free survival was 3 months and median overall survival was 22·4 months. There were two patients with sustained complete responses, both with PTCL-NOS histology. The side effect profile was consistent with prior studies, with pleural effusion being the most common non-haematological toxicity. Exploratory genomic analysis showed two cases of PTCL-NOS with sustained response had a common mutation in LRRK2 and high prevalence of FOXO1 mutation in relapsed/refractory follicular lymphoma.",
keywords = "NHL, dasatinib, mutation analysis, phase 2 study, relapsed/refractory lymphoma",
author = "Umakanthan, {Jayadev M.} and Javeed Iqbal and Batlevi, {Connie L.} and Alyssa Bouska and Smith, {Lynette M} and Valerie Shostrom and Heather Nutsch and William, {Basem M.} and Bociek, {Robert G} and Lunning, {Matthew A} and Bierman, {Philip Jay} and Anas Younes and Armitage, {James Olen} and Vose, {Julie Marie}",
year = "2019",
month = "3",
doi = "10.1111/bjh.15702",
language = "English (US)",
volume = "184",
pages = "744--752",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma

AU - Umakanthan, Jayadev M.

AU - Iqbal, Javeed

AU - Batlevi, Connie L.

AU - Bouska, Alyssa

AU - Smith, Lynette M

AU - Shostrom, Valerie

AU - Nutsch, Heather

AU - William, Basem M.

AU - Bociek, Robert G

AU - Lunning, Matthew A

AU - Bierman, Philip Jay

AU - Younes, Anas

AU - Armitage, James Olen

AU - Vose, Julie Marie

PY - 2019/3

Y1 - 2019/3

N2 - Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. The most common sub-types were diffuse large B-cell lymphoma (24%), follicular lymphoma, grade 1/2 (21%) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; 21%). Most patients were heavily pre-treated, including 42% with more than four prior therapies, 67% with rituximab exposure and 24% with prior autologous transplant. In this cohort, dasatinib showed modest activity in evaluable patients with an objective response rate of 29% (7/24) and clinical benefit rate of 71% (17/24). In 32 patients with outcome data, median progression-free survival was 3 months and median overall survival was 22·4 months. There were two patients with sustained complete responses, both with PTCL-NOS histology. The side effect profile was consistent with prior studies, with pleural effusion being the most common non-haematological toxicity. Exploratory genomic analysis showed two cases of PTCL-NOS with sustained response had a common mutation in LRRK2 and high prevalence of FOXO1 mutation in relapsed/refractory follicular lymphoma.

AB - Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. The most common sub-types were diffuse large B-cell lymphoma (24%), follicular lymphoma, grade 1/2 (21%) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; 21%). Most patients were heavily pre-treated, including 42% with more than four prior therapies, 67% with rituximab exposure and 24% with prior autologous transplant. In this cohort, dasatinib showed modest activity in evaluable patients with an objective response rate of 29% (7/24) and clinical benefit rate of 71% (17/24). In 32 patients with outcome data, median progression-free survival was 3 months and median overall survival was 22·4 months. There were two patients with sustained complete responses, both with PTCL-NOS histology. The side effect profile was consistent with prior studies, with pleural effusion being the most common non-haematological toxicity. Exploratory genomic analysis showed two cases of PTCL-NOS with sustained response had a common mutation in LRRK2 and high prevalence of FOXO1 mutation in relapsed/refractory follicular lymphoma.

KW - NHL

KW - dasatinib

KW - mutation analysis

KW - phase 2 study

KW - relapsed/refractory lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85057741513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057741513&partnerID=8YFLogxK

U2 - 10.1111/bjh.15702

DO - 10.1111/bjh.15702

M3 - Article

C2 - 30520026

AN - SCOPUS:85057741513

VL - 184

SP - 744

EP - 752

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -